{"protocolSection": {"identificationModule": {"nctId": "NCT02062463", "orgStudyIdInfo": {"id": "BFS-AS-40035"}, "secondaryIdInfos": [{"id": "2013-004630-14", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX\u00ae as Compared to SYMBICORT\u00ae TURBOHALER\u00ae as Treatment for Adult Participants With Asthma", "officialTitle": "A 12-Week, Randomized, Open-Label, Parallel-Group Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX\u00ae (160/4.5 and 320/9 mcg) as Compared With SYMBICORT\u00ae TURBOHALER\u00ae (200/6 and 400/12 mcg) as Treatment for Adult Patients With Asthma (The Easy Low Instruction Over Time [ELIOT] Study)", "acronym": "ELIOT"}, "statusModule": {"statusVerifiedDate": "2023-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-05-28", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2015-03-13", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-03-13", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-02-12", "studyFirstSubmitQcDate": "2014-02-12", "studyFirstPostDateStruct": {"date": "2014-02-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2022-09-14", "resultsFirstSubmitQcDate": "2023-09-07", "resultsFirstPostDateStruct": {"date": "2024-03-22", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-09-07", "lastUpdatePostDateStruct": {"date": "2024-03-22", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study is conducted to assess whether training participants on proper use of BF SPIROMAX and Symbicort TURBOHALER will improve their device-handling technique and potentially improve their treatment outcome, that is, better asthma control."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 485, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Stage 1: Empty Spiromax Followed by Empty Turbohaler", "type": "NO_INTERVENTION", "description": "Participants will be trained on the proper use of empty Spiromax followed by empty Turbohaler devices."}, {"label": "Stage 1: Empty Turbohaler Followed by Empty Spiromax", "type": "NO_INTERVENTION", "description": "Participants will be trained on the proper use of empty Turbohaler followed by empty Spiromax devices."}, {"label": "Stage 2: BF Spiromax", "type": "EXPERIMENTAL", "description": "Participants who have currently received 800 to 1000 micrograms (\u03bcg) beclomethasone-equivalent inhaled corticosteroid (ICS) per day will receive budesonide/formoterol twice daily using the BF Spiromax 160/4.5 device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax will be 640 \u03bcg and 18 \u03bcg, respectively. Participants who have currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the BF Spiromax 320/9 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax will be 1280 \u03bcg and 36 \u03bcg, respectively.", "interventionNames": ["Drug: Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX"]}, {"label": "Stage 2: Symbicort Turbohaler", "type": "ACTIVE_COMPARATOR", "description": "Participants who have currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler will be 800 \u03bcg and 24 \u03bcg respectively. Participants who have currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler will be 1600 \u03bcg and 48 \u03bcg respectively.", "interventionNames": ["Drug: SYMBICORT TURBOHALER budesonide and formoterol fumarate"]}], "interventions": [{"type": "DRUG", "name": "Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX", "description": "SPIROMAX (BF) Budesonide and formoterol fumarate dehydrate (160/4.5 and 320/9 \u03bcg)", "armGroupLabels": ["Stage 2: BF Spiromax"], "otherNames": ["SPIROMAX\u00ae"]}, {"type": "DRUG", "name": "SYMBICORT TURBOHALER budesonide and formoterol fumarate", "description": "SYMBICORT\u00ae TURBOHALER\u00ae (200/6 and 400/12 \u03bcg)", "armGroupLabels": ["Stage 2: Symbicort Turbohaler"], "otherNames": ["SYMBICORT\u00ae", "TURBOHALER\u00ae"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Stage 1: Percentage of Participants Achieving Device Mastery", "description": "Device mastery was defined as absence of healthcare professional (HCP)-observed errors by the end of Step 3 of a 6-step standardized device training protocol for empty Spiromax compared to empty Turbohaler. The 6 steps of device training protocol were: Step 1 - Intuitive use; Step 2 - Patient information leaflet; Step 3 - Instructional video; Step 4 - HCP tuition; Step 5 - HCP tuition (1st repeat); Step 6 - HCP tuition (2nd repeat).", "timeFrame": "Baseline (Day 1)"}, {"measure": "Stage 2: Percentage of Participants Maintaining Device Mastery", "description": "Maintenance of device mastery was defined as absence of HCP-observed errors after 12 weeks of device use.", "timeFrame": "Baseline up to Week 12"}], "secondaryOutcomes": [{"measure": "Stage 1: Percentage of Participants Achieving Device Mastery by Step 1", "description": "The number of participants achieving device mastery by Step 1 (no training/intuitive use) of the device training process. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device. The 6 training steps were as follows: Step 1, intuitive use; Step 2, patient device information leaflet; Step 3, instructional video; Step 4, nurse tuition; Step 5, nurse tuition (1st repeat); Step 6, nurse tuition (2nd repeat). After each training step an assessment of device use was carried out by the nurse using a pre-defined list of inhaler errors.", "timeFrame": "Day 1"}, {"measure": "Stage 1: Percentage of Participants Achieving Device Mastery by Step 2", "description": "The number of participants achieving device mastery by Step 2 (patient device information leaflet) of the device training process. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device. The 6 training steps were as follows: Step 1, intuitive use; Step 2, patient device information leaflet; Step 3, instructional video; Step 4, nurse tuition; Step 5, nurse tuition (1st repeat); Step 6, nurse tuition (2nd repeat). After each training step an assessment of device use was carried out by the nurse using a pre-defined list of inhaler errors.", "timeFrame": "Day 1"}, {"measure": "Stage 1: Number of Steps Taken to Achieve Device Mastery", "timeFrame": "Baseline (Day 1)"}, {"measure": "Stage 1: Number of Nurse-Observed Errors", "timeFrame": "Day 1"}, {"measure": "Stage 1: Patient Satisfaction and Preference Questionnaire (PASAPQ) Total Score", "description": "The PASAPQ is a multi-item measure of inhalation device satisfaction and preference designed specifically for participants with asthma and chronic obstructive pulmonary disease. The PASAPQ includes a total of 14 device satisfaction items, including an overall satisfaction item. The total score was the sum of the 13 items related to performance and convenience domains (7 items for performance domain: Questions 1-5, 10-11, and 6 items for convenience domain: Questions 6-9, 12-13). Each PASAPQ item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the total score, the items within each domain were first summed and then transformed to a 0 (least) or 100 (most) point scale, with higher scores indicating greater satisfaction.", "timeFrame": "Baseline (Day 1)"}, {"measure": "Composite Endpoint: Stage 2: Total Number of Observed Errors (Nurse and Technology [Vitalograph Pneumotrac Spirometer])", "description": "Composite score calculated as the sum of nurse observed errors and technology-observed errors.", "timeFrame": "Baseline up to Week 12"}, {"measure": "Stage 2: Number of Technology-Observed Errors (Vitalograph Pneumotrac Spirometer)", "timeFrame": "Week 12"}, {"measure": "Stage 2: Total Number of Handling Errors", "description": "Total number of device handling errors included HCP observed errors and technology observed errors.", "timeFrame": "Baseline up to Week 12"}, {"measure": "Stage 2: Change in Handling Errors From Stage 1 to Stage 2", "description": "The difference in the number of handling errors identified after participant training using the patient device information leaflet at stage 1 and after 12 weeks of treatment (end of stage 2).", "timeFrame": "Baseline (Day 1), Week 12"}, {"measure": "Stage 2: Number of Participants In Pre-specified Treatment Adherence Categories (Assessed by Device Dose Counters)", "description": "Treatment adherence was categorized (as less than or equal to 50%, 51%-70%, 71%-99%, and 100%) and compared across treatment groups using a chi-square test.", "timeFrame": "Baseline up to Week 12"}, {"measure": "Stage 2: Change From Baseline in 6-Item Asthma Control Questionnaire (ACQ) (Excluding Forced Expiratory Volume in 1 Second [FEV1] Question) Score at Weeks 4, 8, and 12", "description": "The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted forced expiratory volume in 1 second (FEV1) on a 7-point scale (0 to 6). The score is the mean of the first 6 questions (excluding the FEV1 question), generating a value from 0 (totally controlled) to 6 (severely uncontrolled). A negative change from Baseline indicates improvement.", "timeFrame": "Baseline, Weeks 4, 8, and 12"}, {"measure": "Stage 2: Change From Baseline in 7-Item ACQ", "description": "The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted FEV1 on a 7-point scale (0 to 6). The ACQ score is the mean of the 7 questions, generating a value from 0 (totally controlled) to 6 (severely uncontrolled). A negative change from Baseline indicates improvement.", "timeFrame": "Baseline, Week 12"}, {"measure": "Stage 2: Time to First Treatment Failure", "description": "Time to treatment failure was defined as change of asthma treatment or treatment for an asthma exacerbation or lower respiratory tract infection.", "timeFrame": "Baseline up to Week 12"}, {"measure": "Stage 2: Number of Participants With Severe Asthma Exacerbations", "description": "Severe asthma exacerbation was defined as a hospitalization or emergency room attendance for asthma, or an acute course of oral corticosteroids (OCS).", "timeFrame": "Week 12"}, {"measure": "Stage 2: Impact of Maintaining Device Mastery on Time to Treatment Failure", "description": "The impact of maintaining device mastery on time to treatment failure (defined as change of asthma treatment or treatment for an asthma exacerbation or lower respiratory tract infection) was assessed by comparing the time to treatment failure for participants with and without device mastery. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device.", "timeFrame": "Baseline Up to Week 12"}, {"measure": "Stage 2: Impact of Maintaining Device Mastery on Asthma Control Questionnaire Score", "description": "The impact of maintaining device mastery on asthma control was assessed by comparing the 7-item ACQ scores for participants with and without device mastery. The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted FEV1 on a 7-point scale (0 to 6). The ACQ score is the mean of the 7 questions, generating a value from 0 (totally controlled) to 6 (severely uncontrolled). Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device.", "timeFrame": "Baseline Up to Week 12"}, {"measure": "Number of Participants With Adverse Events (AEs)", "description": "An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.", "timeFrame": "Baseline up to Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* The participant has a diagnosis of asthma in accordance with Global Initiative for Asthma (GINA) criteria as evidenced by a United Kingdom (UK) quality outcome framework approved Read code (UK diagnostic coding system).\n* The participant is receiving step 3 or 4 therapy for asthma as defined by the British Thoracic Society (BTS) guidelines (daily doses of beclomethasone dipropionate \\[BDP\\]-equivalent ICS) \u2265800 mcg to 2000 \u03bcg as part of fixed- or free combinations with long-acting \u03b22-agonists (LABA).\n* If participant is a female of childbearing potential (post-menarche or less than 2 years post-menopausal or not surgically sterile), the participant must be willing to commit to using a medically accepted method of contraception for the duration of study and 30 days after discontinuing study drug.\n* The participant, as judged by the investigator, must be willing and able to understand risks and benefits of study participation to give informed consent and to comply with all study requirements as specified in this protocol for the entire duration of their study participation.\n* The participant is SPIROMAX and TURBOHALER na\u00efve (no use of a SYMBICORT TURBOHALER device in the last 6 months, minimizing carryover from prior device use).\n* If female and of childbearing potential, the participant must have a negative urine pregnancy test.\n\n  * other criteria apply, please contact the investigator for additional information.\n\nExclusion Criteria:\n\n* The participant has any clinically significant uncontrolled medical condition (treated or untreated) that, in the judgment of the investigator, will cause participation in the study to be detrimental to the participant.\n* The participant has participated in a Teva-sponsored clinical study with BF SPIROMAX in the last 6 months.\n* The participant is a pregnant, attempting to become pregnant, or breast feeding. (Any woman becoming pregnant during the study will be withdrawn from the study.)\n* The participant has used a clinical trial investigational drug within 1 month before the screening visit.\n* The participant has an ongoing asthma exacerbation or has received OCS and/or antibiotics for a lower respiratory condition (proxy measure for identifying an asthma exacerbation and/or lower respiratory infection, suggestive of altered inspiratory capabilities) in the 2 weeks preceding visit 1.\n* The participant is currently receiving any OCS (including long or short courses).\n* The participant has a significant chronic lower respiratory tract disease other than asthma (for example chronic obstructive pulmonary disease \\[COPD\\], cystic fibrosis or interstitial lung disease). Conditions that are not predominant, such as minor degrees of bronchiectasis, are not a reason for exclusion.\n* The participant has a known allergy or severe sensitivity to the constituents of the study drugs (SPIROMAX or TURBOHALER),for example, to lactose or to milk protein.\n\n  * other criteria apply, please contact the investigator for additional information.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Teva Medical Expert, MD", "affiliation": "Teva Branded Pharmaceutical Products R&D, Inc.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Teva Investigational Site 34092", "city": "Axbridge", "zip": "BS26 2BJ", "country": "United Kingdom", "geoPoint": {"lat": 51.28466, "lon": -2.82078}}, {"facility": "Teva Investigational Site 34081", "city": "Babbacombe", "zip": "TQ1 3SL", "country": "United Kingdom", "geoPoint": {"lat": 50.47819, "lon": -3.5176}}, {"facility": "Teva Investigational Site 34103", "city": "Beccles", "zip": "NR34 9NX", "country": "United Kingdom", "geoPoint": {"lat": 52.45936, "lon": 1.56465}}, {"facility": "Teva Investigational Site 34144", "city": "Bishops Stortford", "zip": "CM22 7EH", "country": "United Kingdom", "geoPoint": {"lat": 51.87113, "lon": 0.15868}}, {"facility": "Teva Investigational Site 34066", "city": "Burnhope", "zip": "DH7 0BD", "country": "United Kingdom"}, {"facility": "Teva Investigational Site 34064", "city": "Bury St Edmunds", "zip": "IP30 9QU", "country": "United Kingdom", "geoPoint": {"lat": 52.2463, "lon": 0.71111}}, {"facility": "Teva Investigational Site 34107", "city": "Bury St Edmunds", "zip": "IP32 7EW", "country": "United Kingdom", "geoPoint": {"lat": 52.2463, "lon": 0.71111}}, {"facility": "Teva Investigational Site 34072", "city": "Cheltenham", "zip": "GL50 4DP", "country": "United Kingdom", "geoPoint": {"lat": 51.90006, "lon": -2.07972}}, {"facility": "Teva Investigational Site 34063", "city": "Chippenham", "zip": "SN14 6GT", "country": "United Kingdom", "geoPoint": {"lat": 51.46, "lon": -2.12472}}, {"facility": "Teva Investigational Site 34122", "city": "Chipping Norton", "zip": "OX7 6BW", "country": "United Kingdom", "geoPoint": {"lat": 51.94109, "lon": -1.5453}}, {"facility": "Teva Investigational Site 34134", "city": "Clacton-on-Sea", "zip": "CO15 4DA", "country": "United Kingdom", "geoPoint": {"lat": 51.78967, "lon": 1.15597}}, {"facility": "Teva Investigational Site 34136", "city": "Colchester", "zip": "CO1 2DL", "country": "United Kingdom", "geoPoint": {"lat": 51.88921, "lon": 0.90421}}, {"facility": "Teva Investigational Site 34143", "city": "Colchester", "zip": "CO1 2QS", "country": "United Kingdom", "geoPoint": {"lat": 51.88921, "lon": 0.90421}}, {"facility": "Teva Investigational Site 34111", "city": "Colchester", "zip": "CO2 7GH", "country": "United Kingdom", "geoPoint": {"lat": 51.88921, "lon": 0.90421}}, {"facility": "Teva Investigational Site 34126", "city": "Colchester", "zip": "CO3 4RA", "country": "United Kingdom", "geoPoint": {"lat": 51.88921, "lon": 0.90421}}, {"facility": "Teva Investigational Site 34135", "city": "Colchester", "zip": "CO3 4RY", "country": "United Kingdom", "geoPoint": {"lat": 51.88921, "lon": 0.90421}}, {"facility": "Teva Investigational Site 34120", "city": "Colchester", "zip": "CO7 9PP", "country": "United Kingdom", "geoPoint": {"lat": 51.88921, "lon": 0.90421}}, {"facility": "Teva Investigational Site 34075", "city": "Daventry", "zip": "NN11 4DY", "country": "United Kingdom", "geoPoint": {"lat": 52.25688, "lon": -1.16066}}, {"facility": "Teva Investigational Site 34112", "city": "Daventry", "zip": "NN11 5RA", "country": "United Kingdom", "geoPoint": {"lat": 52.25688, "lon": -1.16066}}, {"facility": "Teva Investigational Site 34083", "city": "East Hunsbury", "zip": "NN4 0NY", "country": "United Kingdom"}, {"facility": "Teva Investigational Site 34145", "city": "East Tillbury", "zip": "RM18 8SD", "country": "United Kingdom"}, {"facility": "Teva Investigational Site 34099", "city": "Exmouth", "zip": "EX8 2JF", "country": "United Kingdom", "geoPoint": {"lat": 50.61723, "lon": -3.40233}}, {"facility": "Teva Investigational Site 34110", "city": "Exmouth", "zip": "EX8 2JF", "country": "United Kingdom", "geoPoint": {"lat": 50.61723, "lon": -3.40233}}, {"facility": "Teva Investigational Site 34102", "city": "Goldhay", "zip": "PE2 5GP", "country": "United Kingdom"}, {"facility": "Teva Investigational Site 34119", "city": "Great Yarmouth", "zip": "NR31 0DW", "country": "United Kingdom", "geoPoint": {"lat": 52.60831, "lon": 1.73052}}, {"facility": "Teva Investigational Site 34079", "city": "Harrogate", "zip": "HG1 5AR", "country": "United Kingdom", "geoPoint": {"lat": 53.99078, "lon": -1.5373}}, {"facility": "Teva Investigational Site 34068", "city": "Harrogate", "zip": "HG1 5JP", "country": "United Kingdom", "geoPoint": {"lat": 53.99078, "lon": -1.5373}}, {"facility": "Teva Investigational Site 34139", "city": "Hemel Henpstead", "zip": "HP1 2LD", "country": "United Kingdom"}, {"facility": "Teva Investigational Site 34142", "city": "Hinckley", "zip": "LE10 1DS", "country": "United Kingdom", "geoPoint": {"lat": 52.5389, "lon": -1.37613}}, {"facility": "Teva Investigational Site 34116", "city": "Huntingdon", "zip": "PE28 4EQ", "country": "United Kingdom", "geoPoint": {"lat": 52.33049, "lon": -0.18651}}, {"facility": "Teva Investigational Site 34113", "city": "Ipswich", "zip": "IP1 6DW", "country": "United Kingdom", "geoPoint": {"lat": 52.05917, "lon": 1.15545}}, {"facility": "Teva Investigational Site 34098", "city": "Lancashire", "zip": "FY4 3AD", "country": "United Kingdom"}, {"facility": "Teva Investigational Site 34128", "city": "Leicester", "zip": "LE2 6UL", "country": "United Kingdom", "geoPoint": {"lat": 52.6386, "lon": -1.13169}}, {"facility": "Teva Investigational Site 34127", "city": "Leicester", "zip": "LE5 4BP", "country": "United Kingdom", "geoPoint": {"lat": 52.6386, "lon": -1.13169}}, {"facility": "Teva Investigational Site 34141", "city": "Leigh-on-Sea", "zip": "SS9 2SQ", "country": "United Kingdom", "geoPoint": {"lat": 51.54297, "lon": 0.64905}}, {"facility": "Teva Investigational Site 34082", "city": "Liskeard", "zip": "PL14 3XA", "country": "United Kingdom", "geoPoint": {"lat": 50.4545, "lon": -4.46517}}, {"facility": "Teva Investigational Site 34146", "city": "Lister House", "zip": "CM18 7LU", "country": "United Kingdom"}, {"facility": "Teva Investigational Site 34147", "city": "Liverpool", "zip": "L36 0UB", "country": "United Kingdom", "geoPoint": {"lat": 53.41058, "lon": -2.97794}}, {"facility": "Teva Investigational Site 34080", "city": "Loughborough", "zip": "LE11 1NH", "country": "United Kingdom", "geoPoint": {"lat": 52.76667, "lon": -1.2}}, {"facility": "Teva Investigational Site 34086", "city": "Lowestoft", "zip": "NR33 8LG", "country": "United Kingdom", "geoPoint": {"lat": 52.4752, "lon": 1.75159}}, {"facility": "Teva Investigational Site 34138", "city": "Luton", "zip": "PU2 9SB", "country": "United Kingdom", "geoPoint": {"lat": 51.87967, "lon": -0.41748}}, {"facility": "Teva Investigational Site 34076", "city": "Manchester", "zip": "OL9 0LH", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "Teva Investigational Site 34109", "city": "Newton Aycliffe", "zip": "DL5 4SE", "country": "United Kingdom", "geoPoint": {"lat": 54.61842, "lon": -1.5719}}, {"facility": "Teva Investigational Site 34106", "city": "Norwich'", "zip": "NR3 2HW", "country": "United Kingdom", "geoPoint": {"lat": 52.62783, "lon": 1.29834}}, {"facility": "Teva Investigational Site 34095", "city": "Norwich", "zip": "NR11 6AA", "country": "United Kingdom", "geoPoint": {"lat": 52.62783, "lon": 1.29834}}, {"facility": "Teva Investigational Site 34108", "city": "Norwich", "zip": "NR12 8DU", "country": "United Kingdom", "geoPoint": {"lat": 52.62783, "lon": 1.29834}}, {"facility": "Teva Investigational Site 34091", "city": "Norwich", "zip": "NR5 0GB", "country": "United Kingdom", "geoPoint": {"lat": 52.62783, "lon": 1.29834}}, {"facility": "Teva Investigational Site 34123", "city": "Norwich", "zip": "NR5 9HA", "country": "United Kingdom", "geoPoint": {"lat": 52.62783, "lon": 1.29834}}, {"facility": "Teva Investigational Site 34085", "city": "Oadby", "zip": "LE2 4PE", "country": "United Kingdom", "geoPoint": {"lat": 52.60621, "lon": -1.08354}}, {"facility": "Teva Investigational Site 34070", "city": "Oldham", "zip": "OL9 8NH", "country": "United Kingdom", "geoPoint": {"lat": 53.54051, "lon": -2.1183}}, {"facility": "Teva Investigational Site 34114", "city": "Orby", "zip": "NN17 1QP", "country": "United Kingdom", "geoPoint": {"lat": 53.18142, "lon": 0.23211}}, {"facility": "Teva Investigational Site 34118", "city": "Oxon", "zip": "OX33 1YJ", "country": "United Kingdom"}, {"facility": "Teva Investigational Site 34137", "city": "Pickering", "zip": "YO18 8BL", "country": "United Kingdom", "geoPoint": {"lat": 54.25, "lon": -0.76667}}, {"facility": "Teva Investigational Site 34124", "city": "Reading", "zip": "RG8 7DP", "country": "United Kingdom", "geoPoint": {"lat": 51.45625, "lon": -0.97113}}, {"facility": "Teva Investigational Site 34089", "city": "Redditch", "zip": "B98 0NR", "country": "United Kingdom", "geoPoint": {"lat": 52.3065, "lon": -1.94569}}, {"facility": "Teva Investigational Site 34100", "city": "Sheringham", "zip": "NR26 8RT", "country": "United Kingdom", "geoPoint": {"lat": 52.94078, "lon": 1.20931}}, {"facility": "Teva Investigational Site 34117", "city": "Stalham", "zip": "NR12 9BU", "country": "United Kingdom", "geoPoint": {"lat": 52.77079, "lon": 1.51783}}, {"facility": "Teva Investigational Site 34105", "city": "Stanley", "zip": "DH9 7TD", "country": "United Kingdom", "geoPoint": {"lat": 54.86796, "lon": -1.69846}}, {"facility": "Teva Investigational Site 34065", "city": "Stowmarket", "zip": "IP14 1NL", "country": "United Kingdom", "geoPoint": {"lat": 52.18893, "lon": 0.99774}}, {"facility": "Teva Investigational Site 34067", "city": "Strensall", "zip": "YO32 5UA", "country": "United Kingdom", "geoPoint": {"lat": 54.03999, "lon": -1.03512}}, {"facility": "Teva Investigational Site 34078", "city": "Swindon", "zip": "SN2 1UU", "country": "United Kingdom", "geoPoint": {"lat": 51.55797, "lon": -1.78116}}, {"facility": "Teva Investigational Site 34140", "city": "Thaxted", "zip": "CM6 2QN", "country": "United Kingdom", "geoPoint": {"lat": 51.95326, "lon": 0.34478}}, {"facility": "Teva Investigational Site 34096", "city": "Thornton-Cleveleys", "zip": "FY5 2TZ", "country": "United Kingdom", "geoPoint": {"lat": 53.87389, "lon": -3.02244}}, {"facility": "Teva Investigational Site 34088", "city": "Trowbridge", "zip": "BA14 8QA", "country": "United Kingdom", "geoPoint": {"lat": 51.31889, "lon": -2.20861}}, {"facility": "Teva Investigational Site 34077", "city": "Trowbridge", "zip": "BA14 9AR", "country": "United Kingdom", "geoPoint": {"lat": 51.31889, "lon": -2.20861}}, {"facility": "Teva Investigational Site 34071", "city": "Waterlooville", "zip": "PO7 5XP", "country": "United Kingdom", "geoPoint": {"lat": 50.88067, "lon": -1.0304}}, {"facility": "Teva Investigational Site 34073", "city": "Waterlooville", "zip": "PO7 7AH", "country": "United Kingdom", "geoPoint": {"lat": 50.88067, "lon": -1.0304}}, {"facility": "Teva Investigational Site 34084", "city": "Wells-Next-Sea", "zip": "NR23 1JP", "country": "United Kingdom"}, {"facility": "Teva Investigational Site 34115", "city": "Wisbech", "zip": "PE14 7RR", "country": "United Kingdom", "geoPoint": {"lat": 52.66622, "lon": 0.15938}}, {"facility": "Teva Investigational Site 34069", "city": "Woodbridge", "zip": "IP12 3DA", "country": "United Kingdom", "geoPoint": {"lat": 52.09332, "lon": 1.32042}}, {"facility": "Teva Investigational Site 34074", "city": "Woodbridge", "zip": "IP12 4FD", "country": "United Kingdom", "geoPoint": {"lat": 52.09332, "lon": 1.32042}}, {"facility": "Teva Investigational Site 34090", "city": "Worcester", "zip": "WR1 2BS", "country": "United Kingdom", "geoPoint": {"lat": 52.18935, "lon": -2.22001}}, {"facility": "Teva Investigational Site 34121", "city": "Wymondham", "zip": "NR18 0RF", "country": "United Kingdom", "geoPoint": {"lat": 52.75978, "lon": -0.74055}}, {"facility": "Teva Investigational Site 34101", "city": "York", "zip": "YO24 4HD", "country": "United Kingdom", "geoPoint": {"lat": 53.95763, "lon": -1.08271}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study was conducted in 2 stages: Stage 1 and 2. In Stage 1, participants were randomly assigned to either empty Spiromax followed by empty Turbohaler or empty Turbohaler followed by empty Spiromax. Stage 2 comprised randomization of eligible participants to the study drugs.", "groups": [{"id": "FG000", "title": "Stage 1: Empty Spiromax Followed by Empty Turbohaler", "description": "Participants were trained on the proper use of empty Spiromax followed by empty Turbohaler devices."}, {"id": "FG001", "title": "Stage 1: Empty Turbohaler Followed by Empty Spiromax", "description": "Participants were trained on the proper use of empty Turbohaler followed by empty Spiromax devices."}, {"id": "FG002", "title": "Stage 2: BF Spiromax", "description": "Participants who had currently received 800 to 1000 micrograms (\u03bcg) beclomethasone-equivalent inhaled corticosteroid (ICS) per day received budesonide/formoterol twice daily using the BF Spiromax 160/4.5 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 640 \u03bcg and 18 \u03bcg, respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 320/9 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 1280 \u03bcg and 36 \u03bcg, respectively."}, {"id": "FG003", "title": "Stage 2: Symbicort Turbohaler", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 800 \u03bcg and 24 \u03bcg respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 1600 \u03bcg and 48 \u03bcg respectively."}], "periods": [{"title": "Crossover Stage 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "243"}, {"groupId": "FG001", "numSubjects": "242"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Full Analysis Set", "comment": "All randomized participants who completed assessments on both study devices (empty Turbohaler and empty Spiromax), permitting a paired analysis of results.", "achievements": [{"groupId": "FG000", "numSubjects": "240"}, {"groupId": "FG001", "numSubjects": "241"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "240"}, {"groupId": "FG001", "numSubjects": "241"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawals during stage 1 were not captured", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Stage 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "197"}, {"groupId": "FG003", "numSubjects": "197"}]}, {"type": "Received at Least 1 Dose of Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "197"}, {"groupId": "FG003", "numSubjects": "197"}]}, {"type": "Full Analysis Set", "comment": "All randomized participants who returned for assessment of maintenance of inhaler technique at Week 12, and who had at least 10 weeks (inclusive) of device use of the inhaler (treatment) to which they were randomly assigned.", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "151"}, {"groupId": "FG003", "numSubjects": "154"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "144"}, {"groupId": "FG003", "numSubjects": "141"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "53"}, {"groupId": "FG003", "numSubjects": "56"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "12"}, {"groupId": "FG003", "numSubjects": "20"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "20"}, {"groupId": "FG003", "numSubjects": "20"}]}, {"type": "Non-Compliance", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Other than specified", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "10"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Randomized analysis set included all randomized participants.", "groups": [{"id": "BG000", "title": "Empty Spiromax Followed by Empty Turbohaler", "description": "Participants were trained on the proper use of empty Spiromax followed by empty Turbohaler devices."}, {"id": "BG001", "title": "Empty Turbohaler Followed by Empty Spiromax", "description": "Participants were trained on the proper use of empty Turbohaler followed by empty Spiromax devices."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "243"}, {"groupId": "BG001", "value": "242"}, {"groupId": "BG002", "value": "485"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.4", "spread": "13.8"}, {"groupId": "BG001", "value": "53.1", "spread": "14.2"}, {"groupId": "BG002", "value": "53.8", "spread": "14.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "152"}, {"groupId": "BG001", "value": "134"}, {"groupId": "BG002", "value": "286"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "91"}, {"groupId": "BG001", "value": "108"}, {"groupId": "BG002", "value": "199"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "White", "measurements": [{"groupId": "BG000", "value": "238"}, {"groupId": "BG001", "value": "235"}, {"groupId": "BG002", "value": "473"}]}, {"title": "Black", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Stage 1: Percentage of Participants Achieving Device Mastery", "description": "Device mastery was defined as absence of healthcare professional (HCP)-observed errors by the end of Step 3 of a 6-step standardized device training protocol for empty Spiromax compared to empty Turbohaler. The 6 steps of device training protocol were: Step 1 - Intuitive use; Step 2 - Patient information leaflet; Step 3 - Instructional video; Step 4 - HCP tuition; Step 5 - HCP tuition (1st repeat); Step 6 - HCP tuition (2nd repeat).", "populationDescription": "Full analysis set (FAS) for Stage 1 included all randomized participants who completed assessments on both study devices (empty Turbohaler and empty Spiromax), permitting a paired analysis of results.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline (Day 1)", "groups": [{"id": "OG000", "title": "Stage 1: Empty Spiromax", "description": "Participants were trained on the proper use of empty Spiromax."}, {"id": "OG001", "title": "Stage 1: Empty Turbohaler", "description": "Participants were trained on the proper use of empty Turbohaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "481"}, {"groupId": "OG001", "value": "481"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "94.4"}, {"groupId": "OG001", "value": "86.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis was performed using a conditional logistic regression model.", "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "Threshold for significance at 0.05 level.", "statisticalMethod": "Chi-squared", "paramType": "Odds Ratio (OR)", "paramValue": "3.77", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.05", "ciUpperLimit": "6.95"}]}, {"type": "PRIMARY", "title": "Stage 2: Percentage of Participants Maintaining Device Mastery", "description": "Maintenance of device mastery was defined as absence of HCP-observed errors after 12 weeks of device use.", "populationDescription": "FAS for Stage 2 included all randomized participants who returned for assessment of maintenance of inhaler technique at Week 12, and who had at least 10 weeks (inclusive) of device use of the inhaler (treatment) to which they were randomly assigned.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline up to Week 12", "groups": [{"id": "OG000", "title": "Stage 2: BF Spiromax", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 160/4.5 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 640 \u03bcg and 18 \u03bcg, respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 320/9 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 1280 \u03bcg and 36 \u03bcg, respectively."}, {"id": "OG001", "title": "Stage 2: Symbicort Turbohaler", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 800 \u03bcg and 24 \u03bcg respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 1600 \u03bcg and 48 \u03bcg respectively."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "58.9"}, {"groupId": "OG001", "value": "53.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis was performed using a conditional logistic regression model.", "nonInferiorityType": "OTHER", "pValue": "0.316", "pValueComment": "Threshold for significance at 0.05 level.", "statisticalMethod": "Chi-squared", "paramType": "Odds Ratio (OR)", "paramValue": "1.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.80", "ciUpperLimit": "1.98"}]}, {"type": "SECONDARY", "title": "Stage 1: Percentage of Participants Achieving Device Mastery by Step 1", "description": "The number of participants achieving device mastery by Step 1 (no training/intuitive use) of the device training process. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device. The 6 training steps were as follows: Step 1, intuitive use; Step 2, patient device information leaflet; Step 3, instructional video; Step 4, nurse tuition; Step 5, nurse tuition (1st repeat); Step 6, nurse tuition (2nd repeat). After each training step an assessment of device use was carried out by the nurse using a pre-defined list of inhaler errors.", "populationDescription": "FAS for Stage 1 included all randomized participants who completed assessments on both study devices (empty Turbohaler and empty Spiromax), permitting a paired analysis of results.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Day 1", "groups": [{"id": "OG000", "title": "Stage 1: Empty Spiromax", "description": "Participants were trained on the proper use of empty Spiromax."}, {"id": "OG001", "title": "Stage 1: Empty Turbohaler", "description": "Participants were trained on the proper use of empty Turbohaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "481"}, {"groupId": "OG001", "value": "481"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33.3"}, {"groupId": "OG001", "value": "11.4"}]}]}]}, {"type": "SECONDARY", "title": "Stage 1: Percentage of Participants Achieving Device Mastery by Step 2", "description": "The number of participants achieving device mastery by Step 2 (patient device information leaflet) of the device training process. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device. The 6 training steps were as follows: Step 1, intuitive use; Step 2, patient device information leaflet; Step 3, instructional video; Step 4, nurse tuition; Step 5, nurse tuition (1st repeat); Step 6, nurse tuition (2nd repeat). After each training step an assessment of device use was carried out by the nurse using a pre-defined list of inhaler errors.", "populationDescription": "FAS for Stage 1 included all randomized participants who completed assessments on both study devices (empty Turbohaler and empty Spiromax), permitting a paired analysis of results.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Day 1", "groups": [{"id": "OG000", "title": "Stage 1: Empty Spiromax", "description": "Participants were trained on the proper use of empty Spiromax."}, {"id": "OG001", "title": "Stage 1: Empty Turbohaler", "description": "Participants were trained on the proper use of empty Turbohaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "481"}, {"groupId": "OG001", "value": "481"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "80.2"}, {"groupId": "OG001", "value": "64.0"}]}]}]}, {"type": "SECONDARY", "title": "Stage 1: Number of Steps Taken to Achieve Device Mastery", "populationDescription": "FAS for Stage 1 included all randomized participants who completed assessments on both study devices (empty Turbohaler and empty Spiromax), permitting a paired analysis of results.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "steps", "timeFrame": "Baseline (Day 1)", "groups": [{"id": "OG000", "title": "Stage 1: Empty Spiromax", "description": "Participants were trained on the proper use of empty Spiromax."}, {"id": "OG001", "title": "Stage 1: Empty Turbohaler", "description": "Participants were trained on the proper use of empty Turbohaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "481"}, {"groupId": "OG001", "value": "481"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1", "lowerLimit": "0", "upperLimit": "12"}, {"groupId": "OG001", "value": "2", "lowerLimit": "0", "upperLimit": "15"}]}]}]}, {"type": "SECONDARY", "title": "Stage 1: Number of Nurse-Observed Errors", "populationDescription": "FAS for Stage 1 included all randomized participants who completed assessments on both study devices (empty Turbohaler and empty Spiromax), permitting a paired analysis of results.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Errors", "timeFrame": "Day 1", "groups": [{"id": "OG000", "title": "Stage 1: Empty Spiromax", "description": "Participants were trained on the proper use of empty Spiromax."}, {"id": "OG001", "title": "Stage 1: Empty Turbohaler", "description": "Participants were trained on the proper use of empty Turbohaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "481"}, {"groupId": "OG001", "value": "481"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.91", "spread": "0.89"}, {"groupId": "OG001", "value": "2.36", "spread": "0.92"}]}]}]}, {"type": "SECONDARY", "title": "Stage 1: Patient Satisfaction and Preference Questionnaire (PASAPQ) Total Score", "description": "The PASAPQ is a multi-item measure of inhalation device satisfaction and preference designed specifically for participants with asthma and chronic obstructive pulmonary disease. The PASAPQ includes a total of 14 device satisfaction items, including an overall satisfaction item. The total score was the sum of the 13 items related to performance and convenience domains (7 items for performance domain: Questions 1-5, 10-11, and 6 items for convenience domain: Questions 6-9, 12-13). Each PASAPQ item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the total score, the items within each domain were first summed and then transformed to a 0 (least) or 100 (most) point scale, with higher scores indicating greater satisfaction.", "populationDescription": "FAS for Stage 1 included all randomized participants who completed assessments on both study devices (empty Turbohaler and empty Spiromax), permitting a paired analysis of results. Here 'overall number of participants analyzed' = participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline (Day 1)", "groups": [{"id": "OG000", "title": "Stage 1: Empty Spiromax", "description": "Participants were trained on the proper use of empty Spiromax."}, {"id": "OG001", "title": "Stage 1: Empty Turbohaler", "description": "Participants were trained on the proper use of empty turbohaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "477"}, {"groupId": "OG001", "value": "477"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "89.80", "lowerLimit": "18.37", "upperLimit": "100.00"}, {"groupId": "OG001", "value": "85.71", "lowerLimit": "14.29", "upperLimit": "100.00"}]}]}]}, {"type": "SECONDARY", "title": "Composite Endpoint: Stage 2: Total Number of Observed Errors (Nurse and Technology [Vitalograph Pneumotrac Spirometer])", "description": "Composite score calculated as the sum of nurse observed errors and technology-observed errors.", "populationDescription": "FAS for Stage 2 included all randomized participants who returned for assessment of maintenance of inhaler technique at Week 12, and who had at least 10 weeks (inclusive) of device use of the inhaler (treatment) to which they were randomly assigned.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "errors", "timeFrame": "Baseline up to Week 12", "groups": [{"id": "OG000", "title": "Stage 2: BF Spiromax", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 160/4.5 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 640 \u03bcg and 18 \u03bcg, respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 320/9 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 1280 \u03bcg and 36 \u03bcg, respectively."}, {"id": "OG001", "title": "Stage 2: Symbicort Turbohaler", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 800 \u03bcg and 24 \u03bcg respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 1600 \u03bcg and 48 \u03bcg respectively."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.50", "spread": "0.68"}, {"groupId": "OG001", "value": "0.82", "spread": "1.10"}]}]}]}, {"type": "SECONDARY", "title": "Stage 2: Number of Technology-Observed Errors (Vitalograph Pneumotrac Spirometer)", "populationDescription": "FAS for Stage 2 included all randomized participants who returned for assessment of maintenance of inhaler technique at Week 12, and who had at least 10 weeks (inclusive) of device use of the inhaler (treatment) to which they were randomly assigned.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Errors", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Stage 2: BF Spiromax", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 160/4.5 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 640 \u03bcg and 18 \u03bcg, respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 320/9 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 1280 \u03bcg and 36 \u03bcg, respectively."}, {"id": "OG001", "title": "Stage 1: Symbicort Turbohaler", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 800 \u03bcg and 24 \u03bcg respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 1600 \u03bcg and 48 \u03bcg respectively."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "0.08"}, {"groupId": "OG001", "value": "0.01", "spread": "0.08"}]}]}]}, {"type": "SECONDARY", "title": "Stage 2: Total Number of Handling Errors", "description": "Total number of device handling errors included HCP observed errors and technology observed errors.", "populationDescription": "FAS for Stage 2 included all randomized participants who returned for assessment of maintenance of inhaler technique at Week 12, and who had at least 10 weeks (inclusive) of device use of the inhaler (treatment) to which they were randomly assigned.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "errors", "timeFrame": "Baseline up to Week 12", "groups": [{"id": "OG000", "title": "Stage 2: BF Spiromax", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 160/4.5 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 640 \u03bcg and 18 \u03bcg, respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 320/9 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 1280 \u03bcg and 36 \u03bcg, respectively."}, {"id": "OG001", "title": "Stage 2: Symbicort Turbohaler", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 800 \u03bcg and 24 \u03bcg respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 1600 \u03bcg and 48 \u03bcg respectively."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.50", "spread": "0.68"}, {"groupId": "OG001", "value": "0.82", "spread": "1.10"}]}]}]}, {"type": "SECONDARY", "title": "Stage 2: Change in Handling Errors From Stage 1 to Stage 2", "description": "The difference in the number of handling errors identified after participant training using the patient device information leaflet at stage 1 and after 12 weeks of treatment (end of stage 2).", "populationDescription": "FAS for Stage 2 included all randomized participants who returned for assessment of maintenance of inhaler technique at Week 12, and who had at least 10 weeks (inclusive) of device use of the inhaler (treatment) to which they were randomly assigned.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Errors", "timeFrame": "Baseline (Day 1), Week 12", "groups": [{"id": "OG000", "title": "Stage 2: BF Spiromax", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 160/4.5 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 640 \u03bcg and 18 \u03bcg, respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 320/9 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 1280 \u03bcg and 36 \u03bcg, respectively."}, {"id": "OG001", "title": "Stage 2: Symbicort Turbohaler", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 800 \u03bcg and 24 \u03bcg respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 1600 \u03bcg and 48 \u03bcg respectively."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.95", "spread": "1.72"}, {"groupId": "OG001", "value": "-2.01", "spread": "2.52"}]}]}]}, {"type": "SECONDARY", "title": "Stage 2: Number of Participants In Pre-specified Treatment Adherence Categories (Assessed by Device Dose Counters)", "description": "Treatment adherence was categorized (as less than or equal to 50%, 51%-70%, 71%-99%, and 100%) and compared across treatment groups using a chi-square test.", "populationDescription": "FAS for Stage 2 included all randomized participants who returned for assessment of maintenance of inhaler technique at Week 12, and who had at least 10 weeks (inclusive) of device use of the inhaler (treatment) to which they were randomly assigned.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline up to Week 12", "groups": [{"id": "OG000", "title": "Stage 2: BF Spiromax", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 160/4.5 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 640 \u03bcg and 18 \u03bcg, respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 320/9 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 1280 \u03bcg and 36 \u03bcg, respectively."}, {"id": "OG001", "title": "Stage 2: Symbicort Turbohaler", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 800 \u03bcg and 24 \u03bcg respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 1600 \u03bcg and 48 \u03bcg respectively."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "154"}]}], "classes": [{"categories": [{"title": "\u226450%", "measurements": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "61"}]}, {"title": "51-70%", "measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "16"}]}, {"title": "71-99%", "measurements": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "71"}]}, {"title": "100%", "measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "6"}]}]}]}, {"type": "SECONDARY", "title": "Stage 2: Change From Baseline in 6-Item Asthma Control Questionnaire (ACQ) (Excluding Forced Expiratory Volume in 1 Second [FEV1] Question) Score at Weeks 4, 8, and 12", "description": "The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted forced expiratory volume in 1 second (FEV1) on a 7-point scale (0 to 6). The score is the mean of the first 6 questions (excluding the FEV1 question), generating a value from 0 (totally controlled) to 6 (severely uncontrolled). A negative change from Baseline indicates improvement.", "populationDescription": "FAS for Stage 2 included all randomized participants who returned for assessment of maintenance of inhaler technique at Week 12, and who had at least 10 weeks (inclusive) of device use of the inhaler (treatment) to which they were randomly assigned. Here 'overall number of participants analyzed' = participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Weeks 4, 8, and 12", "groups": [{"id": "OG000", "title": "Stage 2: BF Spiromax", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 160/4.5 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 640 \u03bcg and 18 \u03bcg, respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 320/9 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 1280 \u03bcg and 36 \u03bcg, respectively."}, {"id": "OG001", "title": "Stage 2: Symbicort Turbohaler", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 800 \u03bcg and 24 \u03bcg respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 1600 \u03bcg and 48 \u03bcg respectively."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "147"}]}], "classes": [{"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "140"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.22", "spread": "0.83"}, {"groupId": "OG001", "value": "-0.33", "spread": "0.81"}]}]}, {"title": "Change at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "140"}, {"groupId": "OG001", "value": "143"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.20", "spread": "0.98"}, {"groupId": "OG001", "value": "-0.30", "spread": "1.04"}]}]}, {"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "147"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.22", "spread": "0.95"}, {"groupId": "OG001", "value": "-0.36", "spread": "1.05"}]}]}]}, {"type": "SECONDARY", "title": "Stage 2: Change From Baseline in 7-Item ACQ", "description": "The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted FEV1 on a 7-point scale (0 to 6). The ACQ score is the mean of the 7 questions, generating a value from 0 (totally controlled) to 6 (severely uncontrolled). A negative change from Baseline indicates improvement.", "populationDescription": "FAS for Stage 2 included all randomized participants who returned for assessment of maintenance of inhaler technique at Week 12, and who had at least 10 weeks (inclusive) of device use of the inhaler (treatment) to which they were randomly assigned. Here 'overall number of participants analyzed' = participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Stage 2: BF Spiromax", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 160/4.5 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 640 \u03bcg and 18 \u03bcg, respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 320/9 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 1280 \u03bcg and 36 \u03bcg, respectively."}, {"id": "OG001", "title": "Stage 2: Symbicort Turbohaler", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 800 \u03bcg and 24 \u03bcg respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 1600 \u03bcg and 48 \u03bcg respectively."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "145"}, {"groupId": "OG001", "value": "149"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.20", "spread": "0.78"}, {"groupId": "OG001", "value": "-0.31", "spread": "0.92"}]}]}]}, {"type": "SECONDARY", "title": "Stage 2: Time to First Treatment Failure", "description": "Time to treatment failure was defined as change of asthma treatment or treatment for an asthma exacerbation or lower respiratory tract infection.", "populationDescription": "FAS for Stage 2 included all randomized participants who returned for assessment of maintenance of inhaler technique at Week 12, and who had at least 10 weeks (inclusive) of device use of the inhaler (treatment) to which they were randomly assigned.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "days", "timeFrame": "Baseline up to Week 12", "groups": [{"id": "OG000", "title": "Stage 2: BF Spiromax", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 160/4.5 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 640 \u03bcg and 18 \u03bcg, respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 320/9 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 1280 \u03bcg and 36 \u03bcg, respectively."}, {"id": "OG001", "title": "Stage 2: Symbicort Turbohaler", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 800 \u03bcg and 24 \u03bcg respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 1600 \u03bcg and 48 \u03bcg respectively."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "76.38", "spread": "21.42"}, {"groupId": "OG001", "value": "73.95", "spread": "24.27"}]}]}]}, {"type": "SECONDARY", "title": "Stage 2: Number of Participants With Severe Asthma Exacerbations", "description": "Severe asthma exacerbation was defined as a hospitalization or emergency room attendance for asthma, or an acute course of oral corticosteroids (OCS).", "populationDescription": "FAS for Stage 2 included all randomized participants who returned for assessment of maintenance of inhaler technique at Week 12, and who had at least 10 weeks (inclusive) of device use of the inhaler (treatment) to which they were randomly assigned.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Stage 2: BF Spiromax", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 160/4.5 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 640 \u03bcg and 18 \u03bcg, respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 320/9 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 1280 \u03bcg and 36 \u03bcg, respectively."}, {"id": "OG001", "title": "Stage 2: Symbicort Turbohaler", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 800 \u03bcg and 24 \u03bcg respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 1600 \u03bcg and 48 \u03bcg respectively."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "154"}]}], "classes": [{"categories": [{"title": "0 asthma exacerbation", "measurements": [{"groupId": "OG000", "value": "139"}, {"groupId": "OG001", "value": "136"}]}, {"title": "1 asthma exacerbation", "measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "17"}]}, {"title": "2 asthma exacerbation", "measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}, {"title": "\u22653 asthma exacerbations", "measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Stage 2: Impact of Maintaining Device Mastery on Time to Treatment Failure", "description": "The impact of maintaining device mastery on time to treatment failure (defined as change of asthma treatment or treatment for an asthma exacerbation or lower respiratory tract infection) was assessed by comparing the time to treatment failure for participants with and without device mastery. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device.", "populationDescription": "FAS for Stage 2 included all randomized participants who returned for assessment of maintenance of inhaler technique at Week 12, and who had at least 10 weeks (inclusive) of device use of the inhaler (treatment) to which they were randomly assigned. Here 'overall number of participants analyzed' = participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days", "timeFrame": "Baseline Up to Week 12", "groups": [{"id": "OG000", "title": "Stage 2: BF Spiromax", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 160/4.5 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 640 \u03bcg and 18 \u03bcg, respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 320/9 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 1280 \u03bcg and 36 \u03bcg, respectively."}, {"id": "OG001", "title": "Stage 1: Symbicort Turbohaler", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 800 \u03bcg and 24 \u03bcg respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 1600 \u03bcg and 48 \u03bcg respectively."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "154"}]}], "classes": [{"title": "Device mastery = Yes", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "82"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "72.99", "spread": "22.38"}, {"groupId": "OG001", "value": "75.93", "spread": "22.59"}]}]}, {"title": "Device mastery = No", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "72"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "81.24", "spread": "19.11"}, {"groupId": "OG001", "value": "71.69", "spread": "26.03"}]}]}]}, {"type": "SECONDARY", "title": "Stage 2: Impact of Maintaining Device Mastery on Asthma Control Questionnaire Score", "description": "The impact of maintaining device mastery on asthma control was assessed by comparing the 7-item ACQ scores for participants with and without device mastery. The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted FEV1 on a 7-point scale (0 to 6). The ACQ score is the mean of the 7 questions, generating a value from 0 (totally controlled) to 6 (severely uncontrolled). Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device.", "populationDescription": "FAS for Stage 2 included all randomized participants who returned for assessment of maintenance of inhaler technique at Week 12, and who had at least 10 weeks (inclusive) of device use of the inhaler (treatment) to which they were randomly assigned. Here 'overall number of participants analyzed' = participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline Up to Week 12", "groups": [{"id": "OG000", "title": "Stage 2: BF Spiromax", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 160/4.5 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 640 \u03bcg and 18 \u03bcg, respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 320/9 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 1280 \u03bcg and 36 \u03bcg, respectively."}, {"id": "OG001", "title": "Stage 2: Symbicort Turbohaler", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 800 \u03bcg and 24 \u03bcg respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 1600 \u03bcg and 48 \u03bcg respectively."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "145"}, {"groupId": "OG001", "value": "149"}]}], "classes": [{"title": "Device mastery = Yes", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "85"}, {"groupId": "OG001", "value": "79"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.25", "spread": "1.05"}, {"groupId": "OG001", "value": "1.35", "spread": "0.95"}]}]}, {"title": "Device mastery = No", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "70"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.46", "spread": "0.97"}, {"groupId": "OG001", "value": "1.37", "spread": "0.97"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Events (AEs)", "description": "An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.", "populationDescription": "The safety population for stage 2 included all participants randomly assigned to treatment who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline up to Week 12", "groups": [{"id": "OG000", "title": "Stage 2: BF Spiromax", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 160/4.5 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 640 \u03bcg and 18 \u03bcg, respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 320/9 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 1280 \u03bcg and 36 \u03bcg, respectively."}, {"id": "OG001", "title": "Stage 2: Symbicort Turbohaler", "description": "Participants who had currently received 800 to 1000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 800 \u03bcg and 24 \u03bcg respectively. Participants who had currently received 1600 to 2000 \u03bcg beclomethasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 1600 \u03bcg and 48 \u03bcg respectively."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}, {"groupId": "OG001", "value": "197"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "113"}, {"groupId": "OG001", "value": "119"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Baseline up to Week 12", "description": "Per planned analysis no adverse events were collected or reported during Stage 1.\n\nFor the purpose of adverse event recording, the study period was defined for each participant as the time period from randomization of treatment in stage 2 through the end of the treatment period.\n\nThe safety population for stage 2 included all participants randomly assigned to treatment who received at least 1 dose of study drug.", "eventGroups": [{"id": "EG000", "title": "Stage 2: BF Spiromax", "description": "Participants who had currently received 800 to 1000 \u03bcg beclometasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 160/4.5 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 640 \u03bcg and 18 \u03bcg, respectively. Participants who had currently received 1600 to 2000 \u03bcg beclometasone-equivalent ICS per day received budesonide/formoterol twice daily using the BF Spiromax 320/9 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax were 1280 \u03bcg and 36 \u03bcg, respectively.", "deathsNumAffected": 0, "deathsNumAtRisk": 197, "seriousNumAffected": 3, "seriousNumAtRisk": 197, "otherNumAffected": 27, "otherNumAtRisk": 197}, {"id": "EG001", "title": "Stage 2: Symbicort Turbohaler", "description": "Participants who had currently received 800 to 1000 \u03bcg beclometasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 800 \u03bcg and 24 \u03bcg respectively. Participants who had currently received 1600 to 2000 \u03bcg beclometasone-equivalent ICS per day received budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 \u03bcg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler were 1600 \u03bcg and 48 \u03bcg respectively.", "deathsNumAffected": 0, "deathsNumAtRisk": 197, "seriousNumAffected": 7, "seriousNumAtRisk": 197, "otherNumAffected": 39, "otherNumAtRisk": 197}], "seriousEvents": [{"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 197}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 197}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 197}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 197}]}, {"term": "Atrioventricular block", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 197}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 197}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 197}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 197}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 197}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 197}]}, {"term": "Postoperative wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 197}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 197}]}, {"term": "Thermal burn", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 197}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 197}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 197}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 197}]}, {"term": "Ovarian mass", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 197}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 197}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 197}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 197}]}, {"term": "Pneumothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 197}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 197}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 197}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 197}]}], "otherEvents": [{"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 16, "numAtRisk": 197}, {"groupId": "EG001", "numEvents": 29, "numAffected": 29, "numAtRisk": 197}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 197}, {"groupId": "EG001", "numEvents": 12, "numAffected": 12, "numAtRisk": 197}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data."}, "pointOfContact": {"title": "Director, Clinical Research", "organization": "Teva Branded Pharmaceutical Products R&D, Inc.", "email": "USMedInfo@tevapharm.com", "phone": "1-888-483-8279"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}, {"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M4800", "name": "Beclomethasone", "relevance": "LOW"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Channel", "relevance": "HIGH"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}